CD33 Antibody (CD33-4D3): sc-59020
- CD33 Antibody (CD33-4D3) is a mouse monoclonal IgG2b κ provided at 200 µg/ml
- raised against CD33 of human origin
- recommended for detection of CD33 of human origin by FCM
- See CD33 (6C5/2): sc-53199 for CD33 antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- m-IgG Fc BP-HRP is the preferred secondary detection reagent for CD33 Antibody (CD33-4D3). This reagent is now offered in a bundle with CD33 Antibody (CD33-4D3) (see ordering information below).
QUICK LINKS
SEE ALSO...
CD33 Antibody (CD33-4D3) is a mouse monoclonal IgG2b antibody that detects CD33 in human samples through flow cytometry (FCM). CD33 is a type I transmembrane glycoprotein predominantly expressed on granulocyte and macrophage precursors in the bone marrow, as well as on monocytes in peripheral blood, making CD33 a crucial marker for distinguishing myelogenous leukemia cells from lymphoid or erythroid leukemias. CD33′s importance lies in its role as a sialic acid-dependent cell adhesion molecule, which facilitates interactions between cells and contributes to the regulation of immune responses. This function is particularly significant in the context of hematopoiesis and the immune system, as CD33 helps maintain the balance between cell proliferation and differentiation. Anti-CD33 antibody (CD33-4D3) is an essential tool for researchers studying hematological malignancies and the underlying mechanisms of immune cell interactions.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CD33 Antibody (CD33-4D3) References:
- The role of CD33 as therapeutic target in acute myeloid leukemia. | Walter, RB. 2014. Expert Opin Ther Targets. 18: 715-8. PMID: 24750020
- Evaluation of CD33 as a genetic risk factor for Alzheimer's disease. | Estus, S., et al. 2019. Acta Neuropathol. 138: 187-199. PMID: 30949760
- Targeting CD33 for acute myeloid leukemia therapy. | Liu, J., et al. 2022. BMC Cancer. 22: 24. PMID: 34980040
- Peripheral level of CD33 and Alzheimer's disease: a bidirectional two-sample Mendelian randomization study. | Gu, X., et al. 2022. Transl Psychiatry. 12: 427. PMID: 36192375
- CD33/TREM2 Signaling Mediates Sleep Deprivation-Induced Memory Impairment by Regulating Microglial Phagocytosis. | Tan, S., et al. 2023. Neuromolecular Med. 25: 255-271. PMID: 36639554
- Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16a/NKG2D Immune-Modulating TriNKET® CC-96191. | Lunn-Halbert, MC., et al. 2024. Cancers (Basel). 16: PMID: 38473239
- Targeting CD33+ Acute Myeloid Leukemia with GLK-33, a Lintuzumab-Auristatin Conjugate with a Wide Therapeutic Window. | Satomaa, T., et al. 2024. Mol Cancer Ther. 23: 1073-1083. PMID: 38561023
- Alzheimer's disease associated isoforms of human CD33 distinctively modulate microglial cell responses in 5XFAD mice. | Eskandari-Sedighi, G., et al. 2024. Mol Neurodegener. 19: 42. PMID: 38802940
- The tandem CD33-CLL1 CAR-T as an approach to treat acute myeloid leukemia. | Wang, H., et al. 2024. Blood Transfus.. PMID: 39133622
- Targeting the membrane-proximal C2-set domain of CD33 for improved CAR T cell therapy. | Fiorenza, S., et al. 2024. Mol Ther Oncol. 32: 200854. PMID: 39224504
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD33 Antibody (CD33-4D3) | sc-59020 | 200 µg/ml | $322.00 | |||
CD33 Antibody (CD33-4D3): m-IgG Fc BP-HRP Bundle | sc-539111 | 200 µg Ab; 10 µg BP | $361.00 |